Can social listening data be used to provide meaningful insights into abuse or inappropriate use of bupropion? (A feasibility analysis) (202115)

Study identification

• EU PAS number:
  EUPAS8375
• Study ID:
  48232
• Official title and acronym:
  Can social listening data be used to provide meaningful insights into abuse or inappropriate use of bupropion? (A feasibility analysis) (202115)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned:12/12/2014

Actual:12/12/2014

Study start date

Planned:30/01/2015

Actual:12/12/2014

Date of final study report

Planned:12/12/2016

Actual:03/06/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)